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responseAbstract Background: Occult HBV infection (OBI) can be deﬁned by the presence of HBV-DNA
in the serum of patients who are negative for HBsAg. The presence of OBI has been associated with
a poor therapeutic response to alpha IFN in many, but not in all studies.
Objective: The aim of our study was to assess the prevalence of OBI in the serum of Egyptian
patients with CHC, and to evaluate its impact on the response to treatment with a combination
of Peg-IFNa and RBV.
Materials and methods: Fifty chronic HCV infected patients who were treated with Peg-IFNa once
a week in combination with RBV for 48 weeks were included in this study. Patients were divided
into two groups, group I which included 25 patients who achieved SVR and group II that included
25 patients who failed to achieve SVR (Non-SVR). Both patient groups were subjected to detailed
questionnaire, clinical examination, routine laboratory investigations and virological studies.
Results: No statistical signiﬁcant difference was found in sex distribution regarding SVR and
Non-SVR. The frequency of patients with low viral load has a statistically signiﬁcant associationepatitis
; CHC,
ic acid
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242 G. El Din Ahmed Elsawaf et al.with SVR patients compared to Non-SVR patients. The frequency of anti-HBc seropositivity has a
statistically signiﬁcant association with the Non-SVR patients compared to SVR patients. Out of 11
anti-HBc positive samples, 10 (90.9%) were positive for the pol and s genes while 9 (81.81%) were
positive for the c gene. About 17 (34%) out of 50 patients included in the study were HBV-DNA
positive. The frequency of HBV-DNA positive HCV patients has a statistically signiﬁcant associa-
tion with Non-SVR patients compared to the SVR patients (p< 0.05).
Conclusion: The prevalence of OBI was higher in our CHCV patients. OBI was signiﬁcantly asso-
ciated with poor response to combined Peg-IFNa and RBV therapy.
ª 2014 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/3.0/).1. Introduction
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infec-
tions represent the main causes of chronic liver disease world-
wide, affecting 350–400 million and 170 million people,
respectively.1 HCV is currently the most signiﬁcant public
health problem in Egypt.2 The recently published Egyptian
Demographic and Health Survey (EDHS) in 2008 estimated
an overall antibody to hepatitis C virus (anti-HCV) prevalence
of 14.7% with an estimated 9.8% of resident Egyptian popula-
tions that are chronically infected.3 Anti-hepatitis B core
(anti-HBc) sero-positivity in the general population in Egypt
is reported to be 10–13%.4
HBV and HCV share common modes of transmission,
thus, simultaneous infection is quite frequent, particularly
where both viruses are endemic as among people with a high
risk for parenteral infections.5 Diagnosis of HBV infection is
usually based on the detection of hepatitis B surface antigen
(HBsAg), and the disappearance of this antigen indicates the
clearance of HBV.6 The extensive application of sensitive
molecular tests such as polymerase chain reaction (PCR) and
real-time PCR has enabled HBV-DNA to be detected in spec-
imens from individuals without serological evidence of chronic
HBV infection.7,8 Occult HBV infection (OBI) can be deﬁned
by the presence of HBV-DNA in the serum of patients who
are negative for HBsAg.5,9 In the last decade, OBI pattern
has been documented and frequently identiﬁed in patients with
chronic hepatitis C (CHC) infection.8 Its prevalence, which
varies according to HBV endemicity, ranges from 30% of
CHC patients in Italy to 80% in Japan.2
The currently recommended therapy for CHC is the combi-
nation of pegylated interferon alpha and ribavirin (Peg-IFNa
and RBV) that proved to be superior to standard IFNa and
RBV. Several virological responses may occur, labeled accord-
ing to their timing relative to treatment. The most important
type of virological responses is the sustained virological
response (SVR), deﬁned as the absence of HCV-ribonucleic
acid (RNA) from serum by a sensitive PCR assay 24 weeks fol-
lowing discontinuation of therapy. More than 50% of patients
can achieve an SVR after 24 weeks (in genotypes 2 and 3) or
after 48 weeks (in genotypes 1 and 4) of this combination ther-
apy, making HCV a potentially curable disease.10 The presence
of OBI has been associated with a poor therapeutic response to
alpha IFN in many,1,5,9 but not in all5,11–13 studies. However,
few studies have documented the response rates to the current
Peg-IFNa and RBV therapy. The aim of our study was to
assess the prevalence of OBI in the serum of Egyptian patientswith CHC, and to evaluate its impact on the response to
treatment with a combination of Peg-IFNa and RBV.
2. Materials and methods
Fifty chronic HCV infected patients who were treated with
180 lg Peg-IFNa-2a or 1.5 lg/kg Peg-IFNa-2b once a week
in combination with RBV (800–1400 mg/day) for 48 weeks
were included in this study.14,15 Those patients were selected
from the outpatient clinic of the Medical Research Institute,
Alexandria University who were eligible and fulﬁlling the cri-
teria for treatment with combined Peg-IFNa and RBV and fol-
lowed up for 48 weeks of treatment. PCR- HCV was done at 0
and 48 weeks of the treatment and after 24 weeks of the end of
treatment where the patients were divided into 2 groups; group
I which included 25 patients who achieved SVR and group II
that included 25 patients who failed to achieve SVR (Non-
SVR). Before enrollment in the study both patient groups were
subjected to detailed questionnaire, clinical examination and
the following laboratory investigations: (a) biochemical studies
(ALT, AST and Bilirubin)16 (b) hematological studies
(Prothrombin activity and Platelets count)17 (c) virological
studies that included: Anti-HCV antibodies and HCV-RNA
(0, 48 and 72 week). After selection of both patient groups
other virological studies were done that included: serological
detection of anti-HBc antibodies, Murex anti-HBc total
(Murex Diagnostics, Chicago, IL)18 and detection of
HBV-DNA (s and c genes) by the SYBR Green technique,19
pol gene by the nested PCR technique.20
Anti-HCV antibodies, third generation ELISA kits
(MUREX ANTI-HCV (VERSION 4) MUREX
BIOTECH.)18
HCV-RNA extraction was done using QIAamp viral RNA
Mini kits (Qiagen) according to the manufacturer’s protocol.
For the quantitative detection of HCV-RNA, it was ampliﬁed
by using (Artus HCV QS-RGQ PCR Kit) reagents based on
the ampliﬁcation and simultaneous detection of a speciﬁc
region of the HCV genome using real-time RT-PCR with
TaqMan probe assay. The ampliﬁcation reaction was per-
formed as follows; 6 ll of HCV RG Master A, 9 ll of HCV
RG Master B and 10 ll of Qiagen extracted RNA were added
to bring the reaction to a ﬁnal volume of 25 ll. Real-time PCR
was performed with the Mx3000P TM (Stratagene) real-time
PCR system. The reaction took place under the following ther-
mal proﬁle; incubation at 50 C for 30 min to transcribe viral
RNA to complementary DNA (cDNA) by RT. This was
followed by AmpliTaq gold activation at 95 C for 10 min,
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95 C for 30 s, followed by annealing at 50 C for 1 min and
extension at 72 C for 30 s, with end point ﬂuorescence
detection.
HBV-DNA extraction was done using QIAamp DNA
Blood Mini kit (Qiagen) according to the manufacturer’s pro-
tocol. The detection of HBV-DNA by SYBR Green real-time
PCR (GeneON GmbH) assay was based on the speciﬁc ampli-
ﬁcation of HBV-DNA using primers targeting the s and c-gene
and detection in real-time with SYBR Green dye (GeneON
Gmb HSYBR Green PCR Kits). The ampliﬁcation reaction
was performed as follows; HBV s and c-gene were ampliﬁed
by using 30 pmol of HBV s and c-gene sense and antisense
primers with 12.5 ll SYBR Green universal PCR master mix
2-fold (GeneON GmbH) and 10 ll of Qiagen extracted
DNA. H2O was added to bring the reaction to a ﬁnal volume
of 25 ll. real-time PCR was performed using the Mx3000P TM
(Stratagene) real-time PCR system. The ampliﬁcation proﬁle
was done as the following; AmpliTaq activation at 95 C for
10 min, followed by 40 cycles of PCR ampliﬁcation, including
denaturation at 95 C for 15 s, annealing at 55 C for 30sec
and extension at 72 C for 1 min. A melting curve analysis
was done to determine the purity and speciﬁcity of the ampli-
ﬁcation product.
HBV-DNA extraction was done using QIAamp DNA
Blood Mini kit (Qiagen). Detection of HBV-DNA was done
by nested PCR using speciﬁc primers for pol genes. The outer
primers (ﬁrst round of PCR) used in this test amplify part
(domain B and C) of the HBV polymerase gene. The ampliﬁed
product of the ﬁrst round PCR was targeted by nested (inner)
primers. Nested ampliﬁcation products were 341 bp long, ana-
lyzed on a 2% agarose gel, and visualized by staining with
Ethidium Bromide (EtBr) at 302 nm. The outer ampliﬁcation
reaction components consisted of; 30 pmol of HBPr134 sense
and HBPr135 antisense primers, 12.5 ll universal PCR master
mix 2-fold (GeneOn GmbH), 10 ll of Qiagen extracted DNA
and H2O was added to bring the reaction to a ﬁnal volume
of 25 ll.
The nested ampliﬁcation components contained 30 pmol of
HBPr75 sense and HBPr 94 antisense primer, 12.5 ll universal
PCR master mix 2-fold (GeneON GmbH), 3 ll of outer ampli-
ﬁed products and H2O was added to bring the reaction to a
ﬁnal volume of 25 ll. The thermal proﬁle was performed as
follows; outer ampliﬁcation proﬁle containing AmpliTaq acti-
vation at 95 C for 10 min, followed by 40 cycles of PCR
ampliﬁcation, including denaturation at 95 C for 30 s, anneal-
ing at 45 C for 30 s and extension at 72 C for 30 s. then the
ﬁnal elongation at 72 C for 10 min. Nested ampliﬁcation ther-
mal proﬁle was similar to the outer ampliﬁcation proﬁle (35
cycles) (see Tables 1 and 2).
3. Results
Among the 50 HCV patients included in this study 52% were
males and 48% were females (Table 3). No signiﬁcant
difference was found in sex distribution regarding SVR and
Non-SVR. Table 4 shows that HCV viral load before
treatment (at 0 week) was signiﬁcantly associated with SVR.
Fifteen patients (60%) out of 25 SVR patients had a viral
load below 800,000 IU/mL compared to eight (32%) of the
Non-SVR patients. Table 5 shows that 11 (22%) out of 50patients included in the study were anti-HBc positive.
anti-HBc seropositivity was 36% of the Non-SVR HCV group
compared to 8% of the SVR group, this was found to be
statistically signiﬁcant.
By comparing the detection of HBV-DNA by conventional
nested PCR (pol gene) in relation to the real-time SYBR Green
technique (s and c genes) we found that, out of 11 anti-HBc
positive samples, 10 (90.9%) were positive for the pol and
s genes while 9 (81.81%) were positive for the c gene (Table
6; Figs. 1 and 2). Among the 17 HBV-DNA positive HCV
patients 70.6% were Non-SVR patients while the remaining
29.4% were SVR patients. This was found to be statistically
signiﬁcant (Table 7).
4. Discussion
There is general agreement that patients infected with HCV
should be considered as a category of individuals with high
prevalence of occult hepatitis B.21 The incidence of OBI in
HCV patients varies greatly, ranging from 0% to 52%.12 In
our study; 34% of HCV patients were positive for OBI. Our
results were in agreement with those reported among Mediter-
ranean countries since HBV-DNA was detectable in about
one-third of HBsAg negative persons infected with HCV in
the Mediterranean basin.22,23
Mrani et al.1 reported that HBV-DNA was found in 1/4 of
French chronic hepatitis C patients regardless of the presence
of anti-HBc. Such an occult HBV co-infection was associated
with more severe liver disease, higher HCV viral load and
decreased response to antiviral therapy irrespective of HCV
genotypes. Fukuda et al.24 and Liu et al.25 reported that the
serum titer of HCV-RNA was visibly higher in patients with
concurrent HBV and HCV infection than those with HCV
mono-infection. Mrani et al.1 also found that HCV viral load
was signiﬁcantly higher in HBV-DNA positive than in negative
patients. Emara et al.12 reported that this seemed to be appli-
cable to genotype 4, where HBV-DNA positive patients in
their study showed higher baseline HCV viral load than
HCV mono-infected patients. Our results agree with these
results as 82.4% of our HBV-DNA positive patients were
associated with high HCV viral load compared to 39.4% of
HBV-DNA negative and this was statistically signiﬁcant.
Early studies reported a higher prevalence of HBV-DNA
detection in anti-HBc-positive than in anti-HBc-negative
patients.24,26 In his study, Marusawa et al.27 found that the
prevalence of anti-HBc is almost 50% in patients with HCV
related chronic liver disease. In the present study 34% of our
HCV cases were positive for HBV-DNA of whom 58.8% were
anti-HBc positive. Chemin et al.28 reported that occult HBV
infection was most frequently seen in patients with anti-HBc
as the only HBV serological marker. On the opposite, Mrani
et al.1 found that OBI was not associated with the presence
of anti-HBc in chronic HCV patients.
Ramia et al.29 found that the overall rate of HBV-DNA in
the HCV-infected patients was 16.3%, compared to the
HBV-DNA rate of 41% in HCV-infected patients who were
anti-HBc alone positive. Our results agree with Ramia et al.29
since 22% of the 50 HCV patients were anti-HBc positive of
whom 90.9% were HBV-DNA positive, on the other hand
78% were anti-HBc negative of whom only 17.9% were
positive for HBV-DNA.
Table 1 Sequences of primer pairs used for PCR to detect HBV genome.
Primer name Nucleotide sequence 50 to 30 Nucleotide position
Surface gene
S-sense AGAACATCGCATCAGGACTC 159–178
S-antisense CATAGGTATCTTGCGAAAGC 642–623
Core gene
C-sense CTGGGAGGAGTTGGGGGA 1730–1747
C-antisense GTAGAAGAATAAAGCCC 2503–2487
Table 2 Sequences of primer pairs used for PCR to detect HBV genome.
Primer name Nucleotide sequence 50 to 30 SEQ ID No.
Outer primer
HBPr134 sense GCTGCTATGCCTCATCTTC 134
HBPr 135 antisense CA(G/A)AGACAAAAGAAAATTGG 135
Nested primer
HBPr 75 sense CAAGGTATGTTGCCCGTTTGTCC 75
HBPr 94 antisense GG(T/C)A(A/T)AAAGGGACTCA(A/C)GATG 94
Table 3 Sex distribution among the 50 HCV patients.
Sex SVR (n= 25) Non-SVR (n= 25) Total
N % N % N %
Female 11 44.0 13 52.0 24 48.0
Male 14 56.0 12 48.0 26 52.0
Figure 2 Gel electrophoresis of nested PCR of pol gene. The
15 ll of PCR product was run on 2% agarose gel at 100 V for 1 h.
Lane 1: DNA ladder 100 bp, Lane 2: positive control, Lane 3:
negative control, Lane 4–12 and 14: positive samples and Lane 13:
negative sample.
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ports the notation that OBI is frequently a late phase of overt
chronic HBV infection or serologically recovered acute HBV
infection. Another possible hypothesis for this ﬁnding is that
HCV infection may block the circulating viral expression ofFigure 1 Detection of HBV s gene by SYBR Green. (A) Dissociation curve of s gene. (B) Ampliﬁcation plot of s gene showing a Ct of 35
cycles.
Table 4 HCV viral load in SVR and Non-SVR HCV patients.
HCV viral load SVR (n= 25) Non-SVR (n= 25)
N % N % P
Low: <800,000 IU/mL 15 60.0 8 32.0 0.047*
High: P800,000 IU/mL 10 40.0 17 68.0
* P< 0.05 (signiﬁcant).
Table 5 Distribution of anti-HBc among the 50 HCV patients.
SVR (n= 25) Non-SVR (n= 25) Total
N % N % N % P
Anti-HBc
Negative 23 92.0 16 64.0 39 78.0 0.017*
Positive 2 8.0 9 36.0 11 22.0
* P < 0.05 (signiﬁcant).
Table 6 Detection of HBV-DNA in 11 anti-HBc positive samples using conventional and real-time PCR techniques.
HBV-DNA SYBR Green PCR Conventional nested PCR
s gene c gene pol gene
n % n % N %
Positive 10 90.90 9 81.81 10 90.90
Negative 1 9.09 2 18.18 1 9.09
Table 7 Distribution of HBV-DNA positivity among SVR and Non-SVR HCV patients.
SVR (n= 25) Non-SVR (n= 25) Total
N % N % n % P
HBV-DNA
Negative (n= 33) 20 80.0 13 52.0 33 66.0
0.037*
Positive (n= 17) 5 20.0 12 48.0 17 34.0
* P< 0.05 (signiﬁcant).
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tocytes may persist.30 Also persistence of low levels of HBV-
DNA in the absence of detectable HBsAg may be due to host
and viral factors suppressing viral replication and keeping the
infection under control.7
Few studies however evaluated the impact of occult hepati-
tis B infection on the current standard treatment of HCV
infection, that is, combination of Peg-IFNa and RBV.21
Caviglia et al.11 concluded that despite the high prevalence rate
of liver HBV DNA in patients with CHC, SVR was not
affected by occult HBV infection. Kao et al.19 reported that
the sustained rates of response to combined alpha IFN and
RBV therapy were similar between chronic HCV patients with
OBI and those without OBI, and thus, low-level HBV infection
did not interfere with the response to combination therapy
against HCV. Kishk et al.31 reported that exposure to HBV
or occult HBV infection in patients with chronic HCV does
not affect the outcome of therapy at weeks 12 and 24.By contrast, Mrani et al.1 reported that sustained response
to IFN and RBV was achieved in 11 (28%) of 40 HBV-DNA
positive cases with chronic hepatitis C, compared with 65
(45%) of the 144 HBV-DNA negative cases (P< 0.05). Cacci-
ola et al.9 reported that the occult HBV was detected in 26 of
55 patients in whom IFN therapy was unsuccessful and in 7 of
28 patients in whom treatment was successful. In the present
study, SVR was achieved in 60.6% of the HBV-DNA negative
chronic HCV patients compared to only 29.4% of the occult
HBV chronic HCV patients. This was statistically signiﬁcant.
The serological pattern consisting of ‘‘anti-HBc alone’’,
namely anti-HBc without both HBsAg and anti-HBs, has
gained increased attention as a possible marker of OBI. The
emerging generally accepted concept is that there is a signiﬁ-
cant, but not absolute, correlation between persistence of
OBI and anti-HBc.32 Our ﬁndings were in agreement with
the previous investigations since out of the 11 anti-HBc
positive CHCV patients 10 (90.9%) were OBI. Ocana et al.33
246 G. El Din Ahmed Elsawaf et al.suggested that anti-HBc determination is useful in OBI diag-
nosis, even when HBV-DNA is available, because of the pos-
sibility of intermittent viremia. Also, the Taormina group
recommended its use as a surrogate marker whenever an
HBV-DNA test is not available to identify potential sero-posi-
tive OBI individuals.33
5. Conclusion
The prevalence of OBI was higher in our CHC patients. OBI
was signiﬁcantly associated with poor response to combined
Peg-IFNa and RBV therapy.
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